Cumberland Pharmaceuticals (CPIX) Q4 2025 earnings summary

Executive summary

• Achieved 31% year-over-year revenue growth in Q4 2025, with full-year revenue up 18% to $44.5 million, meeting double-digit growth targets and strong commercial performance.

• Expanded global reach with regulatory approvals and launches in China, Saudi Arabia, and Mexico, and added Talicia to the portfolio through a joint venture.

• Advanced clinical pipeline, highlighted by breakthrough results in the FIGHT DMD study for ifetroban and new FDA designations.

• Net loss for 2025 improved by $3.6 million to $2.9 million; adjusted earnings reached $1.7 million, a $2.7 million improvement over 2024.

• Cash flow from operations was $4.9 million, up $5.5 million from the prior year.

Financial highlights

• Q4 2025 revenues were $13.7 million, up 31% compared to the same quarter last year.

• Full-year 2025 revenues reached $44.5 million, an 18% increase over 2024.

• Product revenues: Kristalose $10.5M, Sancuso $11.9M, Vibativ $9.5M, Caldolor $4.7M, Talicia $3.3M.

• Operating expenses totaled $47.3 million in 2025.

• Ended 2025 with $76.8 million in assets, $52.3 million in liabilities, and $24.9 million in shareholders' equity.

Outlook and guidance

• Targeting double-digit revenue growth and meaningful positive cash flow from operations in 2026.

• Positioned for continued growth through expanded product portfolio, international launches, and clinical milestones.

• Growth expected from in-line brands, Talicia, and international expansion.

• Focus on leveraging commercial platform and new product launches to drive future revenue.